Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Caris Life Sciences, Inc.CAI · Entity 3706 | See Remarks | September 22, 2026 | September 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Caris Life Sciences, Inc.
Report date September 22, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 174,855 |
Reported balance
After 2026-09-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-22 · Sale · Disposed 7,500 · Balance 174,855 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.7750 to $31.8700, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes shares acquired in a non-reportable transaction under the Caris Life Sciences, Inc. 2025 Employee Stock Purchase Plan (a tax-qualified plan) after the date of the reporting person's previous Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 9,184 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 9,184 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.7750 to $31.8700, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: Includes shares acquired in a non-reportable transaction under the Caris Life Sciences, Inc. 2025 Employee Stock Purchase Plan (a tax-qualified plan) after the date of the reporting person's previous Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2026 Filed Sep 23, 2026 21:06 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | SaleCommon Stock | 7,500 | $31.82 | $238,626.00 |
DisclosureSEC source: 0002071923-26-000007 · wk-form4_1790197601.xml · nonDerivative · entry 1 Denton John Russel · CIK 0002071923 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,855 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.7750 to $31.8700, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes shares acquired in a non-reportable transaction under the Caris Life Sciences, Inc. 2025 Employee Stock Purchase Plan (a tax-qualified plan) after the date of the reporting person's previous Form 4. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:23 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | Tax withholdingCommon Stock | 6,047 | $15.25 | $92,216.75 |
DisclosureSEC source: 0002071923-26-000005 · wk-form4_1779135826.xml · nonDerivative · entry 1 Denton John Russel · CIK 0002071923 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,515 F1 · shares: Shares withheld for the payment of taxes on the vesting and settlement of RSUs. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 22:00 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | GrantCommon Stock | 63,971 | $0.00 | $0.00 |
DisclosureSEC source: 0002071923-26-000002 · wk-form4_1773180021.xml · nonDerivative · entry 1 Denton John Russel · CIK 0002071923 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,562 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 13:12 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | PurchaseCommon Stock | 4,184 | $24.09 | $100,792.56 |
DisclosureSEC source: 0002071923-25-000009 · wk-form4_1762780360.xml · nonDerivative · entry 1 Denton John Russel · CIK 0002071923 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 9,184 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.99 to $24.15, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 22:34 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | PurchaseCommon Stock | 7,500 | $21.00 | $157,500.00 |
DisclosureSEC source: 0001104659-25-061810 · tm2518641-5_4seq1.xml · nonDerivative · entry 3 Denton John Russel · CIK 0002071923 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,591 Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 22:34 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | GrantCommon Stock | 99,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-061810 · tm2518641-5_4seq1.xml · nonDerivative · entry 2 Denton John Russel · CIK 0002071923 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,091 F3 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| March 03, 2025 Filed Jun 23, 2025 22:34 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | GrantStock Option · Derivative | 255,000 | $0.00 Strike: $18.60 | $0.00 |
DisclosureSEC source: 0001104659-25-061810 · tm2518641-5_4seq1.xml · derivative · entry 5 Denton John Russel · CIK 0002071923 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 255,000 shares Expires 2035-03-03 F4 · derivative.exercise_date: The stock option vested 60% at grant and will vest 20% on September 1, 2025 and 20% on September 1, 2026. These securities were previously reported on the Reporting Person's Form 3. Read SEC document |
| March 03, 2025 Filed Jun 23, 2025 22:34 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | Disposition to issuerCommon Stock | 238,230 | $18.60 | $4,431,078.00 |
DisclosureSEC source: 0001104659-25-061810 · tm2518641-5_4seq1.xml · nonDerivative · entry 1 Denton John Russel · CIK 0002071923 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,770 F1 · price: Represents shares of Common Stock surrendered to the Issuer as repayment for an outstanding promissory note. F2 · balance_after: These securities were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.